2023-505737-26-00招募中3 期
A Randomised, Open label, Multicentre, Phase 3 Trial of First line Treatment with Mesenchymal Stromal Cells MC0518 Versus Best Available Therapy in Adult and Adolescent Subjects with Steroid refractory Acute Graft versus host Disease After Allogeneic Haematopoietic Stem Cell Transplantation (IDUNN Trial)
Medac Gesellschaft fuer klinische Spezialprapaerate mbH36 个研究点 分布在 4 个国家目标入组 210 人开始时间: 2024年3月28日最近更新:
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 210
- 试验地点
- 36
- 主要终点
- Overall response (OR) as defined by complete response (CR) or partial response (PR) at Visit Day 28 relative to aGvHD status at baseline (Visit Day 1 before the first treatment).
研究概览
简要总结
Demonstrate the superiority of MC0518 compared to the first used Best Available Therapy (BAT) with respect to ORR in adult and adolescent subjects with SR aGvHD at Visit Day 28 and/or to Demonstrate the superiority of MC0518 compared to the first used BAT with respect to overall survival (OS) in adult and adolescent subjects with SR aGVHD until Visit Month 24
入排标准
- 年龄范围
- 0 years 至 65+ years（18-64 Years, 0-17 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Subject had a previous allogeneic HSCT as indicated for non-malignant (including inborn errors of metabolism, primary immunodeficiencies, haemoglobinopathies, and bone marrow failure syndromes) or haematological malignant disease, irrespective of human leukocyte antigen match
- •Subject has been clinically diagnosed with Grade II to IV aGvHD at the Screening Visit.
- •Subject has experienced failure of previous first line aGvHD treatment (ie, SR aGvHD), defined as: a. aGvHD progression within 3 to 5 days of therapy onset with ≥ 2 mg/kg/day of prednisone equivalent or b. failure to improve within 5 to 7 days of treatment initiation with ≥ 2 mg/kg/day of prednisone equivalent or c. incomplete response after > 28 days of immunosuppressive treatment including at least 5 days with ≥ 2 mg/kg/day of prednisone equivalent.
- •Male or female subject who is ≥ 12 years of age and ≥ 15 kg at the Screening Visit.
- •Subject has an estimated life expectancy > 28 days at the Screening Visit.
- •Subject, if female and of childbearing potential, agrees to use a highly effective contraceptive measure starting at the Screening Visit and continuing throughout the entire trial period. The definition of women of childbearing potential (WOCBP) and a complete list of highly effective contraceptive measures are included in an appendix to the protocol.
- •Subject, if a fertile male, agrees to sexual abstinence or to use a condom during sexual activity with their female partner of childbearing potential or pregnant partner. Additionally, if their partner is a WOCBP, then their partner has to use an additional highly effective contraceptive method during sexual activity starting at the Screening Visit and continuing throughout the entire trial period. For the definition of fertile men and a complete list of highly effective contraceptive measures are included in an appendix to the protocol.
- •Subject or parent(s) / legal guardian(s) have read, understood, and signed the informed consent form (and informed assent form, if applicable) according to national regulations.
排除标准
- •Subject has overt relapse or progression or persistence of the underlying disease at the Screening Visit.
- •Subject has received the last HSCT for a solid tumour disease.
- •Subject has GvHD overlap syndrome at the Screening Visit.
- •Subject has received systemic first-line treatment for aGvHD other than steroids and a prophylaxis with other than calcineurin inhibitors, mammalian target of rapamycin (mTOR) inhibitors, anti-thymocyte globulin (ATG), mycophenolate mofetil (MMF), methotrexate (MTX), and / or cyclophosphamide before the Screening Visit. Please Note: In vitro or in vivo graft manipulation to prevent GvHD (eg, T-cell depletion) during HSCT is permitted. Restart of initial prophylaxis with calcineurin inhibitors or mTOR inhibitors after aGvHD onset is permitted.
- •Subject has a known pregnancy (as confirmed by a positive pregnancy test at the Screening Visit) and or is breastfeeding at the Screening Visit.
- •Subject has received treatment with any other investigational agent within 30 days or 5 half-lives (whichever is longer) before the Screening Visit.
结局指标
主要结局
Overall response (OR) as defined by complete response (CR) or partial response (PR) at Visit Day 28 relative to aGvHD status at baseline (Visit Day 1 before the first treatment).
Overall response (OR) as defined by complete response (CR) or partial response (PR) at Visit Day 28 relative to aGvHD status at baseline (Visit Day 1 before the first treatment).
OS until Visit Month 24, defined as the time from the date of randomisation to the date of death due to any cause
OS until Visit Month 24, defined as the time from the date of randomisation to the date of death due to any cause
次要结局
- FFTF until 6 months, defined as the time from the date of randomisation to the date of the event. An event is defined as death, relapse or progression of the underlying disease, or addition or change to any further systemic immunosuppressive aGvHD therapy. The diagnosis of cGvHD is considered to be a competing event.
- aGvHD response at Visit Day 28 assessed by CR, PR, and NR and at Visit Day 60, Visit Day 100, and Visit Day 180 assessed by OR, CR, PR, and NR relative to baseline.
- Change of aGvHD grade at Visit Day 8, Visit Day 15, Visit Day 22, Visit Day 28, Visit Day 60, Visit Day 100, and Visit Day 180 relative to baseline
- Time to response, defined as the time from the date of the first treatment administration to the date of the first response (CR or PR)
- Duration of the response until Visit Month 24, defined as the time from the date of the first OR (CR or PR) to the date of aGvHD assessed as NR compared with the baseline assessment, or the date of addition or change to any further systemic aGvHD therapy, in responders.
- Best OR until Visit Day 28 defined as the achievement of an OR at any time point up to and including Visit Day 28
- Cumulative dose of steroids given for SR-aGvHD from baseline until Visit Day 60 and until Visit Month 24
- Incidence of and time to cGvHD from Visit Day 60 until Visit Month 24
- Incidence of graft failure (GF) from baseline until Visit Month 24
- Incidence of and time to relapse or progression in subjects with underlying malignant disease from randomisation until Visit Month 24
- Event free survival until Visit Month 24, defined as the time from the date of randomisation to the date of the event. An event is defined as GF, relapse or progression of the underlying disease, or death due to any cause.
- The incidence and severity of all adverse events (AEs) until Visit Day 60 or until 30 days after last administration of trial treatment, whichever is later. Thereafter, the incidence of adverse reactions (ARs) will be documented until Visit Month 24.
- Performance score (Karnofsky / Lansky scale) at Visit Day 8, Visit Day 15, Visit Day 22, Visit Day 28, Visit Day 60, and Visit Day 100 in comparison to the baseline.
- HRQoL measures: EuroQol 5D 5L (EQ 5D 5L) and the Functional Assessment of Cancer Therapy Bone Marrow Transplantation (FACTBMT) at Visit Day 28, Visit Day 60, Visit Day 100, and Visit Day 180 in comparison to the baseline.
研究者
Clinical Trial Information
Scientific
Medac Gesellschaft fuer klinische Spezialprapaerate mbH
研究点 (36)
Loading locations...
相似试验
招募中
2 期
A study to determine how safe MB-CART2019.1 is and how well it works in children and adolescents with B cell neoplasms2023-506348-17-00Miltenyi Biomedicine GmbH12
招募中
2 期
A randomized multicenter Phase II trial evaluating oral pooled fecal microbiotherapy (MaaT033) concomitant to Cemiplimab (CB) versus best investigator’s choice (BIC) in resistance to PD-1/PD-L1 blockade due to antibiotics (ATB) uptake in patients with advanced non-small cell lung cancer (NSCLC) - IMMUNOLIFE22024-517018-14-00Institut Gustave Roussy162
尚未招募
不适用
A Phase II Study to Evaluate the Efficacy and Safety of Anti-HER2 Triple-targeted Drugs Combined With CDK4/6 Inhibitors in Neoadjuvant Therapy for ER-positive HER2-positive Breast Cancer Patients.Breast CancerNCT07290166Fudan University42
招募中
3 期
MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer2023-504816-14-00Merck Sharp & Dohme LLC267
已完成
4 期
This is a study to evaluate dose-flexibility of Upadacitinib in Adult Subjects with Moderate to Severe Atopic Dermatitis2023-504869-23-00AbbVie Deutschland GmbH & Co. KG272